Cytokine-Induced Killer (CIK) cells combined with Fc-engineered CD19 antibodies for the treatment of B-cell hematological malignancies

Cytokine-Induced Killer (CIK) cells combined with Fc-engineered CD19 antibodies for the treatment of B-cell hematological malignancies

Tipologia

Ricerca di base/clinica

Stato

aperto

Copertura

Nazionale

Ruolo dell'Istituto

Capofila

Ente finanziatore

IOV - IRCCS

Anno di finanziamento

2019

Principal Investigator

Dott.ssa Elisa Cappuzzello
Scroll to Top